A dispute between the American Red Cross and the U.S. Justice Department has heated up over the interpretation of U.S. antitrust law. The Justice Department has backed a key legal claim from a biomedical company, Verax Biomedical, against the Red Cross. Lawyers for the Red Cross argued that the nonprofit organization is not subject to the Sherman Act federal antitrust law, but the Justice Department refused and asserted that the Red Cross is separate from the federal government and is liable to the law.
In their lawsuit, Verax Biomedical alleges that the Red Cross is using their market dominance in the field of blood platelets to suppress competition for anti-contamination services. The Red Cross referred to the government’s argument as “novel” and warned that it could lead to other organizations that fulfill ‘vital government functions’ to become liable to federal antitrust law. In opposition, the Justice Department stated the Red Cross “made a misreading of the law”. Verax Biomedical fully supported the Justice Department’s assertions, referring to their statement and arguments as “comprehensive and persuasive”.
Read more: American Red Cross Hit With New Antitrust Suit
Although the Justice Department did not argue that the Red Cross should be found liable for antitrust violations, their argument indicates a possible change in the legal stance towards nonprofit organizations and monopolies. It remains to be seen how this case will unfold, and how other entities may be affected by it. The case is Verax Biomedical Inc v. American National Red Cross, U.S. District Court for the District of Massachusetts, No. 1:23-cv-10335-PBS.
Source: Reuters
Featured News
Judge Appoints Law Firms to Lead Consumer Antitrust Litigation Against Apple
Dec 22, 2024 by
CPI
Epic Health Systems Seeks Dismissal of Antitrust Suit Filed by Particle Health
Dec 22, 2024 by
CPI
Qualcomm Secures Partial Victory in Licensing Dispute with Arm, Jury Splits on Key Issues
Dec 22, 2024 by
CPI
Google Proposes Revised Revenue-Sharing Limits Amid Antitrust Battle
Dec 22, 2024 by
CPI
Japan’s Antitrust Authority Expected to Sanction Google Over Monopoly Practices
Dec 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand